In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...

About one in five patients with cancer who undergo genetic testing are incidentally found to have mutations in their blood ...

One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

A newly identified and rare genetic variant slows the growth of mutated blood stem cells and reduces the risk of leukemia.

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Hundreds of people filled the Hollywood Broadwalk on Saturday for the Waves of Hope 5K, an annual walk and run raising ...

A genetic fault long believed to drive the development of esophageal cancer may in fact play a protective role early in the disease, according to new research published in Nature Cancer. This ...